Physician profile
Mark R Smith
NPI 1568486850
$315.52
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $48.18 · 2021: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $71.11 | 2019-2021 | |
| Astellas Pharma US INC | $45.22 | 2021 | |
| Abbvie INC. | $37.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.89 | 2020 | |
| Merck Sharp & Dohme LLC | $28.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2021 | |
| Avanir Pharmaceuticals, INC. | $22.23 | 2019 | |
| Amarin Pharma, INC. | $14.29 | 2020 | |
| Mylan Specialty L.P. | $13.58 | 2021 | |
| Lilly USA, LLC | $11.77 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.